{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:58Z","timestamp":1791994318241,"version":"4.4.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.588862","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T08:34:47Z","timestamp":1605170087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases"],"prefix":"10.3389","volume":"10","author":[{"given":"Marta","family":"Lagan\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gurizzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Intagliata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Baggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Soto Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brighenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bennati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bidoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv001","article-title":"European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women","volume":"26","author":"Malvezzi","year":"2015","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or Carboplatin\u2013Paclitaxel in Pulmonary Adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1714580","article-title":"Osimertinib as First-Line Treatment in EGFR -Mutated Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Popat","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","article-title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","volume":"89","author":"Kuchuk","year":"2015","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5534-3","article-title":"Clinical analysis of patients with skeletal metastasis of lung cancer","volume":"19","author":"Cho","year":"2019","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1716652","article-title":"EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease","volume":"378","author":"Vaidya","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10870","article-title":"Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor\u2212treated patients with non\u2212small cell lung cancer exhibiting bone metastasis","volume":"18","author":"Cui","year":"2019","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/srep42979","article-title":"Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"B15","first-page":"45","article-title":"Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations","volume":"59","author":"Nagata","year":"2013","journal-title":"Osaka City Med J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2014.01.006","article-title":"EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases","volume":"84","author":"Hendriks","year":"2014","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18759","article-title":"Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/srep18670","article-title":"Natural History of Non-Small-Cell Lung Cancer with Bone Metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0026","article-title":"Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study","volume":"180","author":"Berruti","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0213934","DOI":"10.1371\/journal.pone.0213934","article-title":"Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events","volume":"14","author":"Grisanti","year":"2019","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5489\/cuaj.2377","article-title":"Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma","volume":"9","author":"Iacovelli","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5515","article-title":"Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-017-0054-7","article-title":"EGFR controls bone development by negatively regulating mTOR-signaling during osteoblast differentiation","volume":"25","author":"Linder","year":"2018","journal-title":"Cell Death Differ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201900436RR","article-title":"The role of EGFR signaling in age-related osteoporosis in mouse cortical bone","volume":"33","author":"Liu","year":"2019","journal-title":"FASEB J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1517\/14728222.2016.1154945","article-title":"Wnt signaling as potential therapeutic target in lung cancer","volume":"20","author":"Yang","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.07.010","article-title":"Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis","volume":"353","author":"Xi","year":"2014","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2008.12.019","article-title":"Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells","volume":"278","author":"Chang","year":"2009","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.588862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T08:34:49Z","timestamp":1605170089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.588862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":29,"alternative-id":["10.3389\/fonc.2020.588862"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.588862","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"article-number":"588862"}}